Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046943 · ClinicalTrials.gov registry record · Phase 3
Atrasentan in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00046943 is a Phase 3 study that has completed, run by Abbott.
The verdict
NCT00046943, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG atrasentan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046943
The ClinicalTrials.gov registry entry for NCT00046943 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which atrasentan hydrochloride is the first listed.
NCT00046943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046943 about?
NCT00046943 is a clinical study titled "Atrasentan in Treating Patients With Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.
What is the current status of trial NCT00046943?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-09.
What interventions are being tested in trial NCT00046943?
The interventions under investigation include: atrasentan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00046943?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.